Recombinant proteins in therapeutics: haemophilia treatment as an example
2008
Recombinant Proteins in Haemophilia Treatment
publication
Evidence: high
Author Information
Author(s): Antonio Liras
Primary Institution: Complutense University of Madrid
Hypothesis
Why are recombinant products not used more extensively given their high efficacy and maximum safety?
Conclusion
Recombinant products are safer and more effective than plasma-derived products, but their higher cost limits their wider use.
Supporting Evidence
- Hundreds of therapeutic proteins have been produced recombinantly, with about 50 approved for clinical use.
- Recombinant products have not caused any serious adverse events in their 17 years of clinical use for haemophilia.
- Recombinant proteins are considered the treatment of choice for many current diseases due to their safety.
Takeaway
Scientists can make medicines from genes, which are safer than older methods, but they cost more, so not everyone uses them.
Potential Biases
Potential conflicts of interest may influence the prescription of certain products.
Limitations
The higher cost of recombinant products limits their widespread adoption despite their safety and efficacy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website